A landmark clinical trial is now underway in the United kingdom, poised to reshape prostate cancer screening protocols. The £42 million “Transform” study, funded by Prostate Cancer UK and the National Institute for Health and Care research, seeks to refine early detection methods for a disease that affects one in four Black men and is the most common cancer in men in the UK[1]. Researchers will explore the efficacy of combining MRI scans and DNA analysis via saliva tests,aiming to improve upon the often-inconclusive results of the standard PSA test and ultimately reduce prostate cancer mortality rates.
The Transform trial, funded with £42 million from Prostate Cancer UK and the National Institute for Health and Care Research, has begun inviting eligible men to participate. Participation is by invitation only, and direct self-referral is not currently available.
The study will include men aged 50 to 74, with the age lowered to 45 for Black men, who are at a higher risk of developing and dying from prostate cancer compared to White men. This reflects growing awareness of health disparities and the need for targeted screening approaches.
Researchers will evaluate a combination of rapid prostate MRI scans and saliva tests analyzing DNA. This approach seeks to improve diagnostic accuracy, moving beyond reliance on the PSA test, which has been criticized for its unreliability. The PSA test sometimes detects cancers that don’t require treatment while missing aggressive cancers that need early intervention.
Lead researcher Professor Hashim Ahmed described Transform as a “game-changing” trial, stating the goal is to make prostate cancer diagnosis safer and more effective, and to pave the way for a national, organized screening program in Britain.
Matthew Hobbs, Director of Research at Prostate Cancer UK, cautioned that current methods fail to detect enough aggressive cancers and can cause unnecessary harm to men who undergo treatments – such as urinary incontinence and erectile dysfunction – when they may not have needed them. This highlights the importance of more precise diagnostic tools.
The urgency of improved screening is underscored by the story of Danny Burke, 60, who was diagnosed with advanced prostate cancer that had spread to his bones. He believes an organized screening program starting at age 50 could have saved his life, stating, “If we want to stop 12,000 men dying needlessly every year, this is the obvious solution.” Early detection is a critical factor in improving outcomes for prostate cancer patients.
The trial’s launch comes ahead of an anticipated decision from the National Screening Committee in Britain regarding a recommendation on whether to approve a prostate cancer screening program. The committee previously determined that the harms of screening outweighed the benefits. Initial results from the Transform trial are expected within approximately two years, with plans to expand the study to include up to 300,000 men across the United Kingdom. (BBC)
